In addition, BBR may block invasive metastasis of HCC by inhibiting the PI3K/AKT/mTOR signaling pathway and modulating ECM-related molecules, and significantly reversed drug resistance after combination with sorafenib [140, 141]. Here, AKT1 is linked to hepatocellular carcinoma.